TMDX:NSD-TransMedics Group Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 62.65

Change

+0.95 (+1.54)%

Market Cap

USD 2.07B

Volume

0.93M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.50 (-0.62%)

USD 30.74B
PODD Insulet Corporation

-3.24 (-1.22%)

USD 19.01B
MASI Masimo Corporation

-2.01 (-1.19%)

USD 9.43B
BRKR Bruker Corporation

+0.39 (+0.68%)

USD 9.04B
PRCT Procept Biorobotics Corp

-0.02 (-0.02%)

USD 4.83B
NVCR Novocure Ltd

-0.31 (-1.01%)

USD 3.61B
NARI Inari Medical Inc

-2.21 (-3.99%)

USD 3.25B
LIVN LivaNova PLC

-0.60 (-1.26%)

USD 2.83B
IRTC iRhythm Technologies Inc

-1.73 (-1.91%)

USD 2.67B
QDEL Quidel Corporation

-0.18 (-0.40%)

USD 2.57B

ETFs Containing TMDX

FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.02 (-0.13%)

N/A
CIB0:XETRA VanEck Bionic Engineering.. 0.00 % 0.00 %

-0.10 (-0.13%)

USD 4.87M
CYBG:LSE VanEck Bionic Engineering.. 0.00 % 0.00 %

-0.02 (-0.13%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.63% 57% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.63% 57% F 33% F
Trailing 12 Months  
Capital Gain -20.28% 57% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.28% 57% F 32% F
Trailing 5 Years  
Capital Gain 228.70% 97% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 228.70% 97% N/A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 81.05% 85% B 91% A-
Dividend Return 81.05% 85% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 90.43% 42% F 23% F
Risk Adjusted Return 89.63% 99% N/A 94% A
Market Capitalization 2.07B 90% A- 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.